Use of EP4 receptor antagonists in the treatment of IL-23 mediated diseases

摘要

This invention relates to a compound with EP4 antagonistic activity, or a pharmaceutically acceptable salt with EP4 receptor antagonistic activities, which is useful in the treatment of immune disease or allergy. This invention also relates to a compound of formula (I), (II), (III), (IV), (Va) or (Vb), or a pharmaceutically acceptable salt thereof with EP4 receptor antagonistic activities, which is useful in the treatment of immune disease or allergy. This invention also relates to a pharmaceutical composition for the treatment of immune disease or allergy which comprises a therapeutically effective amount of a compound of formula (I), (II), (III), (IV), (Va) or (Vb), or a pharmaceutically acceptable salt thereof. Further this invention relates to a method for the treatment of immune disease or allergy in an animal subject including a mammalian subject, which comprises administering to the animal subject including a mammalian subject a compound of the formula (I), (II), (III), (IV), (Va) or (Vb), or a pharmaceutically acceptable salt thereof.;

主权项

1. A method for the treatment of psoriasis in an animal subject including a mammalian subject, by inhibition of IL-23 production, which comprises administering to the animal subject including a mammalian subject, a therapeutically effective amount of the compound, 3-[2-(4-{2-ethyl-4,6-dimethyl-1H-imidazo [4,5-c]pyridin-1-yl}phenyl)ethyl]-1-[(4-methylbenzene)sulfonyl] urea or a pharmaceutically acceptable salt thereof.